Jazz Pharmaceuticals (JAZZ) Total Liabilities (2010 - 2026)

Jazz Pharmaceuticals has reported Total Liabilities for 17 years, with the latest figure at $7.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities changed 0.44% year-over-year to $7.3 billion; the trailing twelve-month figure through Mar 2026 stood at $7.3 billion (changed 0.44% YoY), and the FY2025 full-year result was $7.3 billion, down 7.3% from the prior year.
• Total Liabilities for Q1 2026 stood at $7.3 billion, roughly flat from $7.3 billion in the prior quarter.
• The five-year high for Total Liabilities was $8.2 billion in Q1 2022, with the low at $7.2 billion in Q2 2025.
• Average Total Liabilities over 5 years is $7.7 billion, with a median of $7.7 billion recorded in 2023.
• Peak annual rise in Total Liabilities reached 175.8% in 2022, while the deepest fall reached 11.92% in 2022.
• Tracing JAZZ's Total Liabilities over 5 years: stood at $7.7 billion in 2022, then slipped by 1.2% to $7.7 billion in 2023, then gained by 3.42% to $7.9 billion in 2024, then decreased by 7.3% to $7.3 billion in 2025, then declined by 0.18% to $7.3 billion in 2026.
• The last three Total Liabilities figures came in at $7.3 billion (Q1 2026), $7.3 billion (Q4 2025), and $7.4 billion (Q3 2025), per Business Quant data.

Peer Comparison